Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects
Open Access
- 2 February 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 92 (3), 253-261
- https://doi.org/10.1093/jnci/92.3.253
Abstract
BACKGROUND: Advanced-stage neuroblastoma resists conventional treatment; hence, novel therapeutic approaches are required. We evaluated the use of c-myb antisense oligodeoxynucleotides (asODNs) delivered to cells via targeted immunoliposomes to inhibit c-Myb protein expression and neuroblastoma cell proliferation in vitro.METHODS: Phosphorothioate asODNs and control sequences were encapsulated in cationic lipid, and the resulting particles were coated with neutral lipids to produce coated cationic liposomes (CCLs). Monoclonal antibodies directed against the disialoganglioside GD2 were covalently coupled to the CCLs. 3H-labeled liposomes were used to measure cellular binding, and cellular uptake of asODNs was evaluated by dot-blot analysis. Growth inhibition was quantified by counting trypan blue dye-stained cells. Expression of c-Myb protein was examined by western blot analysis. RESULTS: Our methods produced GD2-targeted liposomes that stably entrapped 80%-90% of added c-myb asODNs. These liposomes showed concentration-dependent binding to GD2-positive neuroblastoma cells that could be blocked by soluble anti-GD2 monoclonal antibodies. GD2-targeted liposomes increased the uptake of asODNs by neuroblastoma cells by a factor of fourfold to 10-fold over that obtained with free asODNs. Neuroblastoma cell proliferation was inhibited to a greater extent by GD2-targeted liposomes containing c-myb asODNs than by nontargeted liposomes or free asODNs. GD2-targeted liposomes containing c-myb asODNs specifically reduced expression of c-Myb protein by neuroblastoma cells. Enhanced liposome binding and asODN uptake, as well as the antiproliferative effect, were not evident in GD2-negative cells. CONCLUSIONS: Encapsulation of asODNs into immunoliposomes appears to enhance their toxicity toward targeted cells while shielding nontargeted cells from antisense effects and may be efficacious for the delivery of drugs with broad therapeutic applications to tumor cells.Keywords
This publication has 42 references indexed in Scilit:
- Local administration of antisense phosphorothiate olignucleotides to the p65 subunit of NF–κB abrogates established experimental colitis in miceNature Medicine, 1996
- Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinaseNature Medicine, 1996
- “Megatherapy” for advanced neuroblastoma—Rationale and roleEuropean Journal Of Cancer, 1995
- Clinical strategies for the treatment of neuroblastomaEuropean Journal Of Cancer, 1995
- Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.Proceedings of the National Academy of Sciences, 1995
- Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.Proceedings of the National Academy of Sciences, 1991
- A c- myb Antisense Oligodeoxynucleotide Inhibits Normal Human Hematopoiesis in VitroScience, 1988
- Differential protooncogene expression characterizes histopathologically indistinguishable tumors of the peripheral nervous system.Journal of Clinical Investigation, 1987
- Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma.Proceedings of the National Academy of Sciences, 1984
- Acute leukemia viruses E26 and avian myeloblastosis virus have related transformation-specific RNA sequences but different genetic structures, gene products, and oncogenic propertiesProceedings of the National Academy of Sciences, 1982